Cargando…
396. Clinical Characterization of Long COVID in Mexico
BACKGROUND: Long COVID is defined as the persistence of symptoms after 4 weeks of an acute picture. There is talk of 65 million people affected in the world. In Mexico there are no statistics or studies that explore this entity in the population. METHODS: A descriptive, cross-sectional, and prospect...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677685/ http://dx.doi.org/10.1093/ofid/ofad500.466 |
_version_ | 1785150188584697856 |
---|---|
author | Del Carpio-Orantes, Luis García-Mendez, Sergio Sánchez-Díaz, Jesús Salvador Aguilar-Silva, Andrés Martínez-Rojas, Manuel Jiménez-Flores, Oscar Rodrigo Villalobos-López, Luis Roberto González-Arce, América Alejandrina González-Medel, Karem Samantha Domínguez-Cámara, Rubén Munguía-Sereno, Alvaro Efrén Zamora-Vázquez, Violeta Rosalia Vázquez-Manzano, Quiahuitzin Elizabeth Ortíz-Pérez, Diego Hernández-Martínez, Semiramis Itzel Hernández-Hernández, Sara Nohemí Solís-Sánchez, Ishar Fonseca-Pouchoulen, Victor Alejandro Montano-Montiel, Laura Guadalupe Reich-Sierra, Reynaldo |
author_facet | Del Carpio-Orantes, Luis García-Mendez, Sergio Sánchez-Díaz, Jesús Salvador Aguilar-Silva, Andrés Martínez-Rojas, Manuel Jiménez-Flores, Oscar Rodrigo Villalobos-López, Luis Roberto González-Arce, América Alejandrina González-Medel, Karem Samantha Domínguez-Cámara, Rubén Munguía-Sereno, Alvaro Efrén Zamora-Vázquez, Violeta Rosalia Vázquez-Manzano, Quiahuitzin Elizabeth Ortíz-Pérez, Diego Hernández-Martínez, Semiramis Itzel Hernández-Hernández, Sara Nohemí Solís-Sánchez, Ishar Fonseca-Pouchoulen, Victor Alejandro Montano-Montiel, Laura Guadalupe Reich-Sierra, Reynaldo |
author_sort | Del Carpio-Orantes, Luis |
collection | PubMed |
description | BACKGROUND: Long COVID is defined as the persistence of symptoms after 4 weeks of an acute picture. There is talk of 65 million people affected in the world. In Mexico there are no statistics or studies that explore this entity in the population. METHODS: A descriptive, cross-sectional, and prospective study was carried out using an online survey, in adults who wish to participate and who are living in Mexico from January to March 2023, whose main objective is to characterize patients who present symptoms of Long COVID RESULTS: 336 participants with an average age of 41 years (range 18-79 years), the most affected gender is female (69%); Risk factors are Obesity 41%, Diabetes 16%, Hypertension 15.8%; 43.5% commented that they were healthy before COVID-19. Cases of acute COVID they have suffered, 42.3% comment that 2 previous infections, 29.5% had one and 28.3% 3 or more. 77% refer to mild COVID, 13% to severe COVID, and 10% both. Regarding vaccination, 45% have 3 or more vaccines, 36% 2 vaccines, 9% have one vaccine and 10% have not been vaccinated against COVID-19. The most prevalent symptoms are Neuropsychiatric 90%, Musculoskeletal 88%, Cardiovascular 82%, Gastrointestinal 78%, and Pulmonary 71%. The most frequent Neuropsychiatric symptoms: fatigue 76%, memory disorder 72%, anxiety 65%; Musculoskeletal symptoms are arthralgia 71.4%, myalgia 40%, arthritis 28%. Cardiovascular symptoms are palpitations 58%, tachycardia 38%, precordial pain 27%. Gastrointestinal symptoms are diarrhea 43%, abdominal pain 41%, Colitis 26%. Pulmonary symptoms are chronic cough 40%, persistent expectoration 29%, dyspnea 23%. Other symptoms are alopecia 53.3%, chronic dermatitis 38%, frequent infections after COVID-19 20%, menstrual disorders 17%, thyroid disease 12%, development of autoimmune diseases 9.5%, sexual dysfunction 9%, COVID tests persistently positive 6%, thrombotic events 3.6% (cerebral 0.9%, pulmonary thromboembolism 0.6%, myocardial infarction 0.3%), myocarditis 3.3%, chronic renal failure 2.4% and cancer 1.8%. [Figure: see text] [Figure: see text] CONCLUSION: It is important to characterize this population since it has particularities that make it susceptible to this new entity and the creation of clinical guidelines in the country should be encouraged to begin limiting sequelae. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-10677685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106776852023-11-27 396. Clinical Characterization of Long COVID in Mexico Del Carpio-Orantes, Luis García-Mendez, Sergio Sánchez-Díaz, Jesús Salvador Aguilar-Silva, Andrés Martínez-Rojas, Manuel Jiménez-Flores, Oscar Rodrigo Villalobos-López, Luis Roberto González-Arce, América Alejandrina González-Medel, Karem Samantha Domínguez-Cámara, Rubén Munguía-Sereno, Alvaro Efrén Zamora-Vázquez, Violeta Rosalia Vázquez-Manzano, Quiahuitzin Elizabeth Ortíz-Pérez, Diego Hernández-Martínez, Semiramis Itzel Hernández-Hernández, Sara Nohemí Solís-Sánchez, Ishar Fonseca-Pouchoulen, Victor Alejandro Montano-Montiel, Laura Guadalupe Reich-Sierra, Reynaldo Open Forum Infect Dis Abstract BACKGROUND: Long COVID is defined as the persistence of symptoms after 4 weeks of an acute picture. There is talk of 65 million people affected in the world. In Mexico there are no statistics or studies that explore this entity in the population. METHODS: A descriptive, cross-sectional, and prospective study was carried out using an online survey, in adults who wish to participate and who are living in Mexico from January to March 2023, whose main objective is to characterize patients who present symptoms of Long COVID RESULTS: 336 participants with an average age of 41 years (range 18-79 years), the most affected gender is female (69%); Risk factors are Obesity 41%, Diabetes 16%, Hypertension 15.8%; 43.5% commented that they were healthy before COVID-19. Cases of acute COVID they have suffered, 42.3% comment that 2 previous infections, 29.5% had one and 28.3% 3 or more. 77% refer to mild COVID, 13% to severe COVID, and 10% both. Regarding vaccination, 45% have 3 or more vaccines, 36% 2 vaccines, 9% have one vaccine and 10% have not been vaccinated against COVID-19. The most prevalent symptoms are Neuropsychiatric 90%, Musculoskeletal 88%, Cardiovascular 82%, Gastrointestinal 78%, and Pulmonary 71%. The most frequent Neuropsychiatric symptoms: fatigue 76%, memory disorder 72%, anxiety 65%; Musculoskeletal symptoms are arthralgia 71.4%, myalgia 40%, arthritis 28%. Cardiovascular symptoms are palpitations 58%, tachycardia 38%, precordial pain 27%. Gastrointestinal symptoms are diarrhea 43%, abdominal pain 41%, Colitis 26%. Pulmonary symptoms are chronic cough 40%, persistent expectoration 29%, dyspnea 23%. Other symptoms are alopecia 53.3%, chronic dermatitis 38%, frequent infections after COVID-19 20%, menstrual disorders 17%, thyroid disease 12%, development of autoimmune diseases 9.5%, sexual dysfunction 9%, COVID tests persistently positive 6%, thrombotic events 3.6% (cerebral 0.9%, pulmonary thromboembolism 0.6%, myocardial infarction 0.3%), myocarditis 3.3%, chronic renal failure 2.4% and cancer 1.8%. [Figure: see text] [Figure: see text] CONCLUSION: It is important to characterize this population since it has particularities that make it susceptible to this new entity and the creation of clinical guidelines in the country should be encouraged to begin limiting sequelae. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677685/ http://dx.doi.org/10.1093/ofid/ofad500.466 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Del Carpio-Orantes, Luis García-Mendez, Sergio Sánchez-Díaz, Jesús Salvador Aguilar-Silva, Andrés Martínez-Rojas, Manuel Jiménez-Flores, Oscar Rodrigo Villalobos-López, Luis Roberto González-Arce, América Alejandrina González-Medel, Karem Samantha Domínguez-Cámara, Rubén Munguía-Sereno, Alvaro Efrén Zamora-Vázquez, Violeta Rosalia Vázquez-Manzano, Quiahuitzin Elizabeth Ortíz-Pérez, Diego Hernández-Martínez, Semiramis Itzel Hernández-Hernández, Sara Nohemí Solís-Sánchez, Ishar Fonseca-Pouchoulen, Victor Alejandro Montano-Montiel, Laura Guadalupe Reich-Sierra, Reynaldo 396. Clinical Characterization of Long COVID in Mexico |
title | 396. Clinical Characterization of Long COVID in Mexico |
title_full | 396. Clinical Characterization of Long COVID in Mexico |
title_fullStr | 396. Clinical Characterization of Long COVID in Mexico |
title_full_unstemmed | 396. Clinical Characterization of Long COVID in Mexico |
title_short | 396. Clinical Characterization of Long COVID in Mexico |
title_sort | 396. clinical characterization of long covid in mexico |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677685/ http://dx.doi.org/10.1093/ofid/ofad500.466 |
work_keys_str_mv | AT delcarpioorantesluis 396clinicalcharacterizationoflongcovidinmexico AT garciamendezsergio 396clinicalcharacterizationoflongcovidinmexico AT sanchezdiazjesussalvador 396clinicalcharacterizationoflongcovidinmexico AT aguilarsilvaandres 396clinicalcharacterizationoflongcovidinmexico AT martinezrojasmanuel 396clinicalcharacterizationoflongcovidinmexico AT jimenezfloresoscarrodrigo 396clinicalcharacterizationoflongcovidinmexico AT villaloboslopezluisroberto 396clinicalcharacterizationoflongcovidinmexico AT gonzalezarceamericaalejandrina 396clinicalcharacterizationoflongcovidinmexico AT gonzalezmedelkaremsamantha 396clinicalcharacterizationoflongcovidinmexico AT dominguezcamararuben 396clinicalcharacterizationoflongcovidinmexico AT munguiaserenoalvaroefren 396clinicalcharacterizationoflongcovidinmexico AT zamoravazquezvioletarosalia 396clinicalcharacterizationoflongcovidinmexico AT vazquezmanzanoquiahuitzinelizabeth 396clinicalcharacterizationoflongcovidinmexico AT ortizperezdiego 396clinicalcharacterizationoflongcovidinmexico AT hernandezmartinezsemiramisitzel 396clinicalcharacterizationoflongcovidinmexico AT hernandezhernandezsaranohemi 396clinicalcharacterizationoflongcovidinmexico AT solissanchezishar 396clinicalcharacterizationoflongcovidinmexico AT fonsecapouchoulenvictoralejandro 396clinicalcharacterizationoflongcovidinmexico AT montanomontiellauraguadalupe 396clinicalcharacterizationoflongcovidinmexico AT reichsierrareynaldo 396clinicalcharacterizationoflongcovidinmexico |